Slowing the progression of multiple sclerosis

Slowing the progression of multiple sclerosis
B lymphocytes (purple) in the meningeal vessels (cyan) of mice. Credit: L. Michel et al., Science Translational Medicine (2019)

Over 77,000 Canadians are living with multiple sclerosis, a disease whose causes still remain unknown. Presently, they have no hope for a cure. In a study published in Science Translational Medicine, researchers at the University of Montreal Hospital Research Centre (CRCHUM) identify a molecule named ALCAM which, once blocked, delays the progression of the disease. Their results, obtained from in vitro human and in vivo mouse studies, could lead to the development of a new generation of therapies to treat this autoimmune disease.

Under normal conditions, the blood-brain barrier protects our brain from exposure to harmful elements. For example, it prevents cells of the immune system such as lymphocytes from invading our central nervous system. However, in people with , this barrier is permeable. A large number of lymphocytes manage to migrate into the brain and deteriorate its tissues (by destruction of the myelin sheath that protects the neurons and enables the transmission of nerve impulses).

"In our study, we show for the first time that a molecule called ALCAM (Activated Leukocyte Cell Adhesion Molecule), expressed by B cells, controls their entry into the brain via blood vessels. It allows them to migrate to the other side of the in mice and humans. By blocking this molecule in mice, we were able to reduce the flow of B cells into their brains and, as a result, slow the progression of the disease," said Dr. Alexandre Prat, a researcher at the CRCHUM, professor at the Université de Montréal and holder of the Canada Research Chair in Multiple Sclerosis.

In the animal model of multiple sclerosis, the administration of an antibody that blocks ALCAM impairs the capacity of B lymphocytes to infiltrate the brain and spinal cord. Credit: Alexandre Prat

B cells contribute to the progressive phase of multiple sclerosis. Certain medications, commonly known as anti-B-cell drugs, reduce its progression and the resulting disability.

"The molecule ALCAM is expressed at higher levels on the B of people with multiple sclerosis. By specifically targeting this molecule, we will now be able to explore other therapeutic avenues for the treatment of this disease," said Dr. Prat.

In the animal model of multiple sclerosis, the administration of an antibody that blocks ALCAM impairs the capacity of B lymphocytes to infiltrate the brain and spinal cord. Credit: Alexandre Prat

Multiple sclerosis can cause symptoms such as fatigue, lack of coordination, vision problems, cognitive impairment and mood changes. One in every 385 Canadians have the disease, including 20,000 people in Quebec. Sixty per cent of adults with multiple sclerosis are between the ages of 20 and 49 and women are three times more likely than men to be diagnosed with it.


Explore further

Discovery of a treatment to block the progression of multiple sclerosis

More information: L. Michel el al., "Activated leukocyte cell adhesion molecule regulates B lymphocyte migration across central nervous system barriers," Science Translational Medicine (2019). stm.sciencemag.org/lookup/doi/ … scitranslmed.aaw0475
Journal information: Science Translational Medicine

Citation: Slowing the progression of multiple sclerosis (2019, November 13) retrieved 6 December 2019 from https://medicalxpress.com/news/2019-11-multiple-sclerosis.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
72 shares

Feedback to editors

User comments